Back to top
Top
U.S. flag

An official website of the United States government

Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer

Compare Versions of: "Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer"

The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.

Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.

Compare 2026 version to

Table Options
Measure Information 2026 Performance Period
Title Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer
CMS eCQM ID CMS646v6
CBE ID* Not Applicable
MIPS Quality ID 481
Measure Steward Oregon Urology
Description

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging

Measure Scoring Proportion measure
Measure Type Process
Stratification

None

Risk Adjustment

None

Rationale

Bladder cancer is ranked 10th for new cancer cases in 2020 and is the ninth leading cause of cancer death in the United States. There are 81,400 estimated new cases in 2020 and 17,980 estimated deaths in 2020. In 2016, an estimated 699,450 people were living with bladder cancer in the...

Show more >
Clinical Recommendation Statement

Intravesical BCG should be administered within 6 months of the initial diagnosis of non-muscle invasive bladder cancer. It may be administered 3-4 weeks after resection, but there needs to be pathological tumor confirmation and must be withheld if there is traumatic catheterization,...

Show more >
Improvement Notation

Higher score indicates better quality

Definition

Intravesical - Within the urinary bladder

Bacillus Calmette-Guerin (BCG) - A live attenuated strain of Mycobacterium bovis, first indicated as a tuberculosis vaccine, has had widespread use in intravesical immunotherapy since the 1970's.

Tumor location: urinary bladder

Histology: urothelial...

Show more >
Guidance

Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.

The BCG dose can be full or partial and can be from any lot or manufacturer. This eCQM is a patient-based measure.

Telehealth encounters are not eligible for this measure...

Show more >
Initial Population

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer with bladder cancer staging within 6 months before to 6 months after the start of the measurement period and a qualified encounter in the measurement period

Denominator

Equals Initial Population

Denominator Exclusions

Immunosuppressed patients, includes HIV and immunocompromised state, with a diagnosis prior to Bladder Cancer Staging.

Immunosuppressive drug therapy starting on or before Bladder Cancer Staging.

Active Tuberculosis diagnosis during the Bladder Cancer Staging.

Mixed histology urothelial...

Show more >
Numerator

Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series: BCG is initiated within 6 months of the bladder cancer staging

Numerator Exclusions

None

Denominator Exceptions

Unavailability of BCG within 6 months after Bladder Cancer Staging

Telehealth Eligible No
Next Version No Version Available
Previous Version

Header

TRN

Measure Section

Source of Change

Changed the 'eCQM Identifier (Measure Authoring Tool)' field name to 'CMS ID' based on tooling updates.

CMS ID

Standards/Technical Update

Updated the eCQM version number.

eCQM Version Number

Annual Update

Updated the generic measurement period from 'January 1, 20XX through December 31, 20XX' to specify 'January 1, 2026 through December 31, 2026' based on tooling updates.

Measurement Period

Standards/Technical Update

Updated copyright.

Copyright

Annual Update

Revised 'Improvement Notation' field to read 'Higher score indicates better quality' for concision.

Improvement Notation

Annual Update

Changed 'Numerator Exclusions' field to read 'None' instead of 'Not Applicable' when no exclusions are present.

Numerator Exclusions

Standards/Technical Update

Updated bladder staging sequence so that it reads in consistent order throughout measure.

Multiple Sections

Measure Lead

Updated grammar, wording, and/or formatting to improve readability and consistency.

Multiple Sections

Annual Update

Logic

TRN

Measure Section

Source of Change

Updated Measure Primary CQL Library Name from 'IntravesicalBacillusCalmetteGuerinForBladderCancer' to 'CMS646IntravesicalBCGforBladderCancerQDM' for alignment with the CQL Style Guide.

Definitions

Standards/Technical Update

Updated the version number of the Global Common Functions Library to v9.0.000 and the library name from 'MATGlobalCommonFunctionsQDM' to 'CQMCommonQDM.'

Definitions

Annual Update

Updated definition name from 'Has Most Recent Bladder Cancer Tumor Staging is Ta HG, Tis, T1' to 'Has Most Recent Bladder Cancer Tumor Staging is T1, Tis, Ta HG' so that tumor staging sequence reads in consistent order throughout measure.

Definitions

Measure Lead

Updated CQL logic to include 'day of' for timing precision where appropriate.

Definitions

Measure Lead

Updated the names of CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.

Definitions

Standards/Technical Update

Updated Measure Primary CQL Library Name from 'IntravesicalBacillusCalmetteGuerinForBladderCancer' to 'CMS646IntravesicalBCGforBladderCancerQDM' for alignment with the CQL Style Guide.

Functions

Standards/Technical Update

Updated the version number of the Global Common Functions Library to v9.0.000 and the library name from 'MATGlobalCommonFunctionsQDM' to 'CQMCommonQDM.'

Functions

Annual Update

Value Set

The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.

TRN

Measure Section

Source of Change

Replaced Value Set 'Active Tuberculosis for Urology Care' (2.16.840.1.113762.1.4.1151.56) with 'Tuberculosis for Urology Care' (2.16.840.1.113762.1.4.1248.351).

Terminology

Annual Update

Replaced Value Set 'BCG Bacillus Calmette Guerin for Urology Care' (2.16.840.1.113762.1.4.1151.52) with Value Set 'Bacillus Calmette Guerin for Urology Care' (2.16.840.1.113762.1.4.1248.353).

Terminology

Annual Update

Replaced Value Set 'Bladder Cancer for Urology Care' (2.16.840.1.113762.1.4.1151.45) with Value Set 'Bladder Cancer for Urology Care' (2.16.840.1.113762.1.4.1248.354).

Terminology

Annual Update

Replaced Value Set 'Chemotherapy Agents for Advanced Cancer' (2.16.840.1.113762.1.4.1151.60) with Value Set 'Chemotherapy Agents for Advanced Cancer' (2.16.840.1.113762.1.4.1248.355).

Terminology

Annual Update

Replaced Value Set 'Cystectomy for Urology Care'(2.16.840.1.113762.1.4.1151.55) with Value Set 'Cystectomy for Urology Care' (2.16.840.1.113762.1.4.1248.358).

Terminology

Annual Update

Value Set 'HIV' (2.16.840.1.113883.3.464.1003.120.12.1003): Deleted 6 ICD10CM codes (O98.711, O98.712, O98.713, O98.719, O98.72 O98.73) based on review by technical experts, SMEs and/or public feedback.

Terminology

Annual Update

Replaced Value Set 'Immunocompromised Conditions' (2.16.840.1.113883.3.666.5.1940) with Value Set 'Immunocompromised Conditions' (2.16.840.1.113762.1.4.1248.363).

Terminology

Annual Update

Replaced Value Set 'Immunosuppressive Drugs for Urology Care' (2.16.840.1.113762.1.4.1151.32) with Value Set 'Immunosuppressive Drugs for Urology Care' (2.16.840.1.113762.1.4.1248.364).

Terminology

Annual Update

Replaced Value Set 'Mixed histology urothelial cell carcinoma for Urology Care' (2.16.840.1.113762.1.4.1151.39) with Value Set 'Mixed Histology Urothelial Cell Carcinoma for Urology Care' (2.16.840.1.113762.1.4.1248.365).

Terminology

Annual Update

Value Set 'Office Visit' (2.16.840.1.113883.3.464.1003.101.12.1001): Added 1 SNOMEDCT code (185349003) based on review by technical experts, SMEs and/or public feedback.

Terminology

Annual Update

Replaced Value Set 'ONC Administrative Sex' (2.16.840.1.113762.1.4.1) with Value Set 'Federal Administrative Sex' (2.16.840.1.113762.1.4.1021.121) to represent Supplemental Data Element 'SDE Sex' based on revised standards.

Terminology

Standards/Technical Update

Replaced Value Set 'Unavailability of Bacillus Calmette Guerin for urology care' (2.16.840.1.113762.1.4.1151.44) with Value Set 'Unavailability of Bacillus Calmette Guerin for Urology Care' (2.16.840.1.113762.1.4.1248.369).

Terminology

Annual Update

Last Updated: May 07, 2025